Drug Profile
Research programme: inflammation therapy - BioLineRx
Alternative Names: BL-3030Latest Information Update: 04 Feb 2008
Price :
$50
*
At a glance
- Originator Ben Gurion University
- Developer BioLineRx
- Class
- Mechanism of Action Phospholipase A2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 04 Feb 2008 No development reported - Preclinical for Inflammation in Israel (unspecified route)
- 02 Oct 2006 Preclinical trials in Inflammation in Israel (unspecified route)